The Impact of Human Recombinant Erythropoietin on Renal Function in Patients with Chronic Kidney Disease

Ahmad Khatibinezhad; Raheb Ghorbani; Alireza Soleimani; Farhad Malek; Mojgan Jalalzadeh; Mohamad Reza Tamadon; Mojtaba Malek

Nephro-Urology Monthly

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

The Impact of Human Recombinant Erythropoietin on Renal Function in Patients with Chronic Kidney Disease

Author(s):

Ahmad Khatibinezhad,

Raheb Ghorbani,

Alireza Soleimani,

Farhad Malek,

Mojgan Jalalzadeh,

Mohamad Reza Tamadon¹,

Mojtaba Malek^2,*

1Department of Internal Medicine, Semnan University of Medical Sciences, Semnan, IR Iran

2Endocrine research center (Firozgar), Institute of Endocrinology and Metabolism, Tehran University of Medical Sciences, Tehran, IR Iran

Nephro-Urology Monthly:Vol. 3, issue 2; 114-116

Published online:Apr 30, 2011

Article type:Research Article

Received:Sep 18, 2010

Accepted:Jan 04, 2011

How to Cite:Ahmad KhatibinezhadRaheb GhorbaniAlireza SoleimaniFarhad MalekMojgan JalalzadehMohamad Reza TamadonMojtaba Maleket al.The Impact of Human Recombinant Erythropoietin on Renal Function in Patients with Chronic Kidney Disease.Nephro-Urol Mon.3(2):114-116.

Abstract

Background: Chronic kidney disease (CKD) is a worldwide health problem. But despite to new routes of dialysis, mortality and morbidity is high. One of the most common symptom of CKD is anemia, especially is more obvious in stages 3 and 4.

Objectives: In this study, the effects of erythropoietin on renal function were assessed by measurement of serum creatinine level.

Patients and Methods: Twenty three adult patients with CKD in the stages 3 and 4, enrolled in study and serum creatinine level was monthly measured three months before need to prescribe the erythropoietin due to anemia resulting from CKD (hemoglobin less than 12g/dl) and continued 6 months after administration of the drug. Based on patients' needs, the drug was administered subcutaneously in a dose of 4000-6000 units per week so patients' hemoglobin level became more than 12g/dL. During the study, all patients who required to dialysis or kidney transplantation were excluded from the study

Results: Mean of creatinine and 1/creatinine values in 4 stages including three-month before intervention, time to intervention, and the three months after the intervention and the six month after the intervention were 2.17 and 0.50; 2.45 and 0.45; 2.41 and 0.47; 2.30 and 0.49 respectively which were not statistically significant.

Conclusion: The administration of recombinant human erythropoietin in stage 3 and 4 of chronic kidney disease, improves anemia with no impact on renal function.

Keywords

Erythropoietin

Chronic kidney failure

Creatinine

Fulltext

Full text is available in PDF

comments